Molecule Information

General Information of the Molecule (ID: Mol01286)

Name	Long non-protein coding RNA 968 (LINC00968) ,Homo sapiens
Synonyms	LINC00968 Click to Show/Hide
Molecule Type	LncRNA
Gene ID	100507632
Location	chr8:56494923-56559823[-]
Ensembl ID	ENSG00000246430
HGNC ID	HGNC:48727
*Click to Show/Hide the Complete Species Lineage*
Kingdom: Metazoa Phylum: Chordata Class: Mammalia Order: Primates Family: Hominidae Genus: Homo Species: Homo sapiens

Type(s) of Resistant Mechanism of This Molecule

EADR: Epigenetic Alteration of DNA, RNA or Protein

Drug Resistance Data Categorized by Drug

Approved Drug(s)

3 drug(s) in total

Click to Show/Hide the Full List of Drugs

Doxorubicin

Click to Show/Hide

Drug Sensitivity Data Categorized by Their Corresponding Mechanisms
Epigenetic Alteration of DNA, RNA or Protein (EADR)			Click to Show/Hide
Disease Class: Breast cancer				[1]
Sensitive Disease	Breast cancer [ICD-11: 2C60.3]			Disease Info
Sensitive Drug	Doxorubicin			Drug Info
Molecule Alteration	Expression		Up-regulation
Experimental Note	Revealed Based on the Cell Line Data
Cell Pathway Regulation	Wnt2/Beta-catenin signaling pathway		Inhibition	hsa04310
In Vitro Model	MCF-7 cells	Breast	Homo sapiens (Human)	CVCL_0031
	KPL-4 cells	Breast	Homo sapiens (Human)	CVCL_5310
In Vivo Model	Nude mouse xenograft model			Mus musculus
Experiment for Molecule Alteration	RT-qPCR,Northern blot
Experiment for Drug Resistance	CCK8 assay; Colony formation assay
Mechanism Description	Long non-coding RNA LINC00968 attenuates drug (Doxorubicin; Vincristine; Taxol) resistance of breast cancer cells through inhibiting the Wnt2/beta-catenin signaling pathway by regulating WNT2.

Paclitaxel

Click to Show/Hide

Drug Sensitivity Data Categorized by Their Corresponding Mechanisms
Epigenetic Alteration of DNA, RNA or Protein (EADR)			Click to Show/Hide
Disease Class: Breast cancer				[1]
Sensitive Disease	Breast cancer [ICD-11: 2C60.3]			Disease Info
Sensitive Drug	Paclitaxel			Drug Info
Molecule Alteration	Expression		Up-regulation
Experimental Note	Revealed Based on the Cell Line Data
Cell Pathway Regulation	Wnt2/Beta-catenin signaling pathway		Inhibition	hsa04310
In Vitro Model	MCF-7 cells	Breast	Homo sapiens (Human)	CVCL_0031
	KPL-4 cells	Breast	Homo sapiens (Human)	CVCL_5310
In Vivo Model	Nude mouse xenograft model			Mus musculus
Experiment for Molecule Alteration	RT-qPCR,Northern blot
Experiment for Drug Resistance	CCK8 assay; Colony formation assay
Mechanism Description	Long non-coding RNA LINC00968 attenuates drug resistance of breast cancer cells through inhibiting the Wnt2/beta-catenin signaling pathway by regulating WNT2.

Vincristine

Click to Show/Hide

Drug Sensitivity Data Categorized by Their Corresponding Mechanisms
Epigenetic Alteration of DNA, RNA or Protein (EADR)			Click to Show/Hide
Disease Class: Breast cancer				[1]
Sensitive Disease	Breast cancer [ICD-11: 2C60.3]			Disease Info
Sensitive Drug	Vincristine			Drug Info
Molecule Alteration	Expression		Up-regulation
Experimental Note	Revealed Based on the Cell Line Data
Cell Pathway Regulation	Wnt2/Beta-catenin signaling pathway		Inhibition	hsa04310
In Vitro Model	MCF-7 cells	Breast	Homo sapiens (Human)	CVCL_0031
	KPL-4 cells	Breast	Homo sapiens (Human)	CVCL_5310
In Vivo Model	Nude mouse xenograft model			Mus musculus
Experiment for Molecule Alteration	RT-qPCR,Northern blot
Experiment for Drug Resistance	CCK8 assay; Colony formation assay
Mechanism Description	Long non-coding RNA LINC00968 attenuates drug resistance of breast cancer cells through inhibiting the Wnt2/beta-catenin signaling pathway by regulating WNT2.

References

Ref 1	Long non-coding RNA LINC00968 attenuates drug resistance of breast cancer cells through inhibiting the Wnt2/Beta-catenin signaling pathway by regulating WNT2. J Exp Clin Cancer Res. 2019 Feb 21;38(1):94. doi: 10.1186/s13046-019-1100-8.